GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells

Song, Bin; Ge, Hong; Pu, Chenwei; Li, Ning

doi:10.1186/s12890-021-01800-3

Cited by 3 publications

(2 citation statements)

References 48 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, long-term studies are needed to evaluate the effect of teduglutide on cell viability. Indeed, a few studies have shown that teduglutide may have a beneficial effect on cell survival [22][23][24], but specific long-term studies are required in order to understand precisely the effect of teduglutide on enterocyte viability.…”

Section: Discussionmentioning

confidence: 99%

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes

et al. 2023

View full text Add to dashboard Cite

Teduglutide, a GLP-2 analogue, has been available in France since 2015 to treat short-bowel-syndrome (SBS)-associated chronic intestinal failure (CIF) but it remains very expensive. No real-life data on the number of potential candidates are available. The aim of this real-life study was to assess teduglutide initiation and outcomes in SBS-CIF patients. All SBS-CIF patients cared for in an expert home parenteral support (PS) center between 2015 and 2020 were retrospectively included. Patients were divided into two subpopulations: prevalent patients, already cared for in the center before 2015, and incident patients, whose follow-up started between 2015 and 2020. A total of 331 SBS-CIF patients were included in the study (156 prevalent and 175 incident patients). Teduglutide was initiated in 56 patients (16.9% of the cohort); in 27.9% of prevalent patients and in 8.0% of incident patients, with a mean annual rate of 4.3% and 2.5%, respectively. Teduglutide allowed a reduction in the PS volume by 60% (IQR: 40–100), with a significantly higher reduction in incident versus prevalent patients (p = 0.02). The two- and five-year treatment retention rates were 82% and 64%. Among untreated patients, 50 (18.2%) were considered ineligible for teduglutide for non-medical reasons. More than 25% of prevalent SBS patients were treated with teduglutide compared to 8% of incident patients. The treatment retention rate was >80% at 2 years, which could be explained by a careful selection of patients. Furthermore, this real-life study confirmed the long-term efficacy of teduglutide and showed a better response to teduglutide in incident patients, suggesting a benefit in early treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Finally, the sections were sealed with neutral gum and observed under the microscope. Photographs were captured under the microscope and saved for subsequent analysis of the number of positively stained cells using ImageJ software (v1.6.0), and the area of positively stained cells was determined with quantitative analysis [39].…”

Section: Immunohistochemistrymentioning

confidence: 99%

NEDD4L-Sp1 ubiquitination inhibits GlyT1 to promote prominent hippocampal neuronal damage and apoptosis, leading to cognitive dysfunction in diabetic rats

Yang

Zhū

et al. 2023

Preprint

View full text Add to dashboard Cite

Diabetes-associated cognitive dysfunction(DACD) is one of the neurological complications of diabetes, and it mainly involves the hippocampal region of the brain and affects the learning and memory functions of the body. There are many studies on the pathogenesis of DACD, but there is a lack of in-depth studies on the underlying molecular mechanism, which poses a great challenge to drug development. In this study, we focused on the molecular mechanism by which signal transduction by the glycine transporter GlyT1 participates in the development of DACD and systematically elucidated the processes of synaptic plasticity and apoptosis in hippocampal neurons. The results showed that when neurons were exposed to a high-glucose environment, low levels of GlyT1 inhibited the activation of the PI3K/AKT/mTOR pathway to promote neuronal apoptosis; additionally, GlyT1 regulated NMDR expression to regulate glycine concentrations in order to reduce synaptic plasticity. The transcription factor Sp1 bound to the GlyT1 promoter region and regulated GlyT1 expression, so we explored whether Sp1 expression was regulated by the protease-ubiquitin system, resulting in decreased Sp1 levels.In conclusion, In conclusion, our study systematically demonstrated the biological function and molecular mechanism by which GlyT1 participates in DACD development, elucidated the upstream and downstream mechanisms of GlyT1 regulation, provided reliable molecular targets for DACD treatment, and enhanced the understanding of the mechanism underlying DACD development.

show abstract

Graph-Based Spatial Proximity of Super-Resolved Protein–Protein Interactions Predicts Cancer Drug Responses in Single Cells

Zhang,

Cai,

Wang

et al. 2024

Cel. Mol. Bioeng.

View full text Add to dashboard Cite

GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells

Cited by 3 publications

References 48 publications

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes

NEDD4L-Sp1 ubiquitination inhibits GlyT1 to promote prominent hippocampal neuronal damage and apoptosis, leading to cognitive dysfunction in diabetic rats

Graph-Based Spatial Proximity of Super-Resolved Protein–Protein Interactions Predicts Cancer Drug Responses in Single Cells

Contact Info

Product

Resources

About